DMK Pharmaceuticals Corporation
DMKPQ · OTC
12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
|---|---|---|---|---|
| Revenue | $5 | $2 | $3 | $22 |
| % Growth | 115.3% | -20.5% | -87.4% | – |
| Cost of Goods Sold | $8 | $7 | $6 | $16 |
| Gross Profit | -$3 | -$5 | -$4 | $6 |
| % Margin | -60.9% | -211.1% | -127.9% | 29.1% |
| R&D Expenses | $10 | $11 | $8 | $11 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $12 | $16 | $20 | $25 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $22 | $27 | $28 | $36 |
| Operating Income | -$25 | -$32 | -$32 | -$30 |
| % Margin | -526.9% | -1,452% | -1,141% | -135.7% |
| Other Income/Exp. Net | -$1 | -$3 | -$4 | $1 |
| Pre-Tax Income | -$26 | -$35 | -$36 | -$28 |
| Tax Expense | $0 | $0 | $0 | -$1 |
| Net Income | -$26 | -$46 | -$49 | -$28 |
| % Margin | -556.7% | -2,074.9% | -1,778.8% | -124.4% |
| EPS | -12.37 | -22.25 | -44.57 | -36.16 |
| % Growth | 44.4% | 50.1% | -23.3% | – |
| EPS Diluted | -12.37 | -22.25 | -44.57 | -36.16 |
| Weighted Avg Shares Out | 2 | 2 | 1 | 1 |
| Weighted Avg Shares Out Dil | 2 | 2 | 1 | 1 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $1 | $1 | $2 | $3 |
| EBITDA | -$24 | -$31 | -$34 | -$25 |
| % Margin | -495.7% | -1,387% | -1,206.7% | -113.4% |